Science for Sale: Law Project for Psychiatric Rights

PsychRights
Law Project for
Psychiatric Rights

Science for Sale

Data based medicine and clinical judgement, by David Healy, Derelie Mangin, and David Antonuccio, International Journal of Risk & Safety in Medicine 25 (2013) 111–121
Pharmaceutical research and development: what do we get for all that money? by Donald W Light and Joel R Lexchin, British Medical Journal, BMJ 2012;344:e4348 doi: 10.1136/bmj.e4348 (Published 7 August 2012)
Reporting Bias in Industry-Supported Medication Trials Presented at the American Psychiatric Association Meeting, by Serijan Sen, MD, PhD, & May Prabhu, MD, MSc,LLB, Journal of Clinical Psychopharmacology,Volume 32, Number 3, June 2012, Letters to the Editor.
A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations with Industry: A Pernicious Problem Persists, by Lisa Cosgrove and Sheldon Krimsky, Essay: Plos Medicine, Vol. 9; Iss. 3 (2012).

Pro Publica's Dollars for Docs
Compilation of payments from Drug Companies to doctors
Challenging Medical Ghostwriting in US Courts, by Xavier Bosch1, Bijan Esfandiari and Leemon McHenry, Public Library of Science (PLoS) Medicine, January 2012, Vol.9, Iss. 1, e1001163.
How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be Revised, by Alastair Matheson, Public Library of Science-Medicine, Vol 8:8 (2011).
Being the Ghost in the Machine: A Medical Ghostwriter's Personal View, by Linda Logdberg, Public Library of Science-Medicine, Vol 8:8 (2011).
Why Does Academic Medicine Allow Ghostwriting? A Prescription for Reform, by Jonathan Leo & Jeffrey R. Lacasse & Andrea N. Cimino, Springer, DOI 10.1007/s12115-011-9455-2 (2011)
Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Articles, by Simon Stern, and Trudo Lemmens, PLoS Medicine, Vol.8, Iss. 8 (2011)
Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments, by Michelle Roseman, BA; Katherine Milette, BS; Lisa A. Bero, PhD; James C. Coyne, PhD; Joel Lexchin, MD; Erick H. Turner, MD; and Brett D. Thombs, PhD, Journal of the American Medical Association, Vol 305, No. 10 (2011).
Complaint of Scientific Misconduct against Dwight L. Evans, Laszlo Gyulai; Charles Nemeroff, Gary S. Sachs and Charles L. Bowden, to the United States Office of Research Integrity, July 8, 2011.
Clinical Social Work and the Biomedical Industrial Complex, by Tomi Gomory, Stephen E. Wong, David Cohen and Jeffrey Lacasse, Journal of Sociology and Social Welfare, in press, December 2010.
“Under the radar”: Nurse Practitioner Prescribers and Pharmaceutical Industry Promotions, by Elissa C. Ladd, PhD, Rn, FNP-BC; Diane Feeney Mahoney, PhD, APRN, BC, FGSA, FAAN; and Srinivas Emani, PhD, Journal of Managed Care, Vol. 16: No. 12; e358-e-362 (December, 2010).
Med Schools Flunk at Keeping Faculty Off Pharma Speaking Circuit, by Tracy Weber and Charles Orsntein, Pro Publica, December 19, 2010.
Drug Maker Wrote Book Under 2 Doctors’ Names, Documents Say, by Duff Wilson, The New York Times, November 29, 2010.
- POGO Letter to NIH, November 29,2010.
Doctors and Drug Companies: Still Cozy after All These Years, by David Henry, PLOS Medicine, Vol. 7, Issue 11, November 2010.
Lies, Damned Lies, and Medical Science, by David H. Freedman, The Atlantic, November, 2010.
Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study, by Andreas Lundh, Marija Barbateskovic, Asbjørn Hrobjartsson, and Peter C. Gøtzsche, Plos Medicine, Volume 7,| Issue 10 , October, 2010.
Missing clinical trial data: setting the record straight, by Fiona Godlee, editor, Elizabeth Loder, associate editor, British Medical Journal, October 12, 2010.
Commentary: Ghostwriting and Academic Medicine, by Jonathan Leo and JeffreyLacasse, The Chronicle of Higher Education, July 19, 2010.
Ghostwriting in Medical Literature, Minority Staff Report, U.S. Senate Committee on Finance, Sen. Charles Grassley, Ranking Member, June 24, 2010.
Psychiatrists' Relationships With Pharmaceutical Companies: Part of the Problem or Part of the Solution?, by Thomas R. Insel, MD JAMA, 2010;303(12):1192-1193.
Ghostwriting at Elite Academic Medical Centers in the United States, by Jeffrey R. Lacasse, Jonathan Leo, Public Library of Science (PLoS), Vol 7, Iss 2 (2010).
From Evidence-based Medicine to Marketing-based Medicine: Evidence from Internal Industry Documents, Glen I. Spielmans & Peter I. Parry, Bioethical Inquiry, DOI 10.1007/s11673-010-9208-8 (2010).
A Case Study of Salami Slicing: Pooled Analyses of Duloxetine for Depression, by Glen I. Spielmans, Tracey L. Biehn, and Dustin L. Sawrey, Psychotherapy and Psychosomatics, 2010;79:97–106.
July 30, 2009, letter from National Institute of Mental Health to Emory University.
Ghostwriting: The Dirty Little Secret of Medical Publishing That Just Got Bigger; Editorial from the PLoS Medicine Editors, September 2009 | Volume 6 | Issue 9 | e1000156.
The Neurontin Legacy -- Marketing throuh Misinformation and Manipulation, by C. Seth Landefeld, M.D., and Michael A. Steinman, M.D., New England Journal of Medicine, 360;2, 103-106 (2009).
Side Effects | Are Doctors' Loyalties Divided? Drug Firms' Cash Skews Doctor Classes: Company-funded UW Courses Often Favor Medicine, Leave Out Side Effects, by Susanne Rust and John Fauber, Journal Sentinel (Wis), March 29, 2009.
Clinical trials and drug promotion: Selective reporting of study 329, by Jon N. Jureidini, Leemon B. McHenry, and Peter R. Mansfield, International Journal of Risk & Safety in Medicine 20 (2008) 73–81.
Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation, Kristin Rising, Peter Bacchetti, Lisa Bero, PLoS Medicine, Vol. 5:11 1561-1570 (November 2008).
Publication Bias and the Pharmaceutical Industry: The Case of Lamotrigine in Bipolar Disorder, by S. Nassir Ghaemi, MD, MPH; Arshia A. Shirzadi, DO; Megan Filkowski, B, Medscape J Med. 2008;10(9):211.
Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis, by Kirby Lee, Peter Bacchetti, and Ida Sim, Plos Medicine, September 2008, Vol.5, Issue 9, e191.
Our Censored Journals, by David Healy, in Medicine, Mental Health, Science, Religion and Well-being (A.R.Singh and S.A. Singh eds), MSM, 6 Jan - Dec 2008, p244-256.
Contract Research Organisations: Truly independent research? by Jeanne Lenzer, medical investigative journalist, British Medical Journal, August 18, 2008.
Is There and (Unbiased) Doctor in the House? by Jeanne Lenzer and Shannon Brownlee, British Medical Journal, 2008;337:a930, July 23, 2008.
State Medical Board Responses to an Inquiry on Physician Research Misconduct, by Sefan P. Kruszewski, M.D., Richard P. Paczynski, MD., and Marzana Bialy, Journal of Medical Lisensure and Discipline, Vol. 94, No. 1: 16-22 (2008).
Editorial: Impugning the Integrity of Medical Science: The Adverse Effects of Industry Influence, by Catherine D. DeAngelis, MD, MPH and Phil B. Fontanarosa, MD, MBA, Journal of the American Medical Association (JAMA), 2008;299(15):1833-1835.
Guest Authorship and Ghostwriting in Publications Related to Rofecoxib [Vioxx]: A Case Study of Industry Documents From Rofecoxib Litigation, by Joseph S. Ross, MD, MHS, Kevin P. Hill, MD, MHS, David S. Egilman, MD, MPH, and Harlan M. Krumholz, MD, SM, Journal of the American Medical Association (JAMA), 2008—Vol 299, No. 15: 1800-1812.
Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry? by Sergio Sismondo, PLOS, September 2007, Volume 4, Issue 9, e286.
The engineers of human souls & academia, by David Healy, MD, Epidemiologia e Psichiatria Sociale, 16, 3, 2007.
Influence of Drug Company Authorship and Sponsorship on Drug Trial Outcomes, Tongeji Tunaraza and Rob Poole, British Journal of Psychiatry, 191, 82-83 (2007).
The Growth of Psychopharmacology in the 1990s: Evidence-based practice or irrational exuberance, by Robert Rosenheck, International Journal of Law and Psychiatry, 2005, Vol. 28, 467-483. Extensive review of research into SRI antidepressants and atypical antipsychotics shows research skewed by drug company dominance and financial ties; proposed is an independent scientific agency with broad responsibility in research and monitoring.
Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles, by An-Wen Chen et. al., JAMA, 2004, Vol. 291, No. 20, 2457-2465. Reporting of clinical trials shows that medical research protocols and results were more often than not presented incompletely and out of context, in support of the treatment or drug under study.
Forum: Financial Conflicts of Interest in Psychiatry, The Journal of the World Psychiatry Association, February, 2007.
Publication Bias, Data Ownership, and the Funding Effect in Science: Threats to the Integrity of Biomedical Research, by S. Krimsky, in Rescuing Science from Politics: Regulation and the Distortion of Scientific Research, Edited by W. Wagner and R. Steinzor. Cambridge University Press, 2006
Manufacturing Consensus, by David Healy, Culture, Medicine and Psychiatry, (2006) 30: 135-56.
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review, by Anders W Jørgensen, Jørgen Hilden, Peter C Gøtzsche, British Medical Journal (BMJ), BMJ, doi:10.1136/bmj.38973.444699.0B (published 6 October 2006). This study found that industry supported reviews of drugs should be read with caution because they were less transparent, had few reservations about methodological limitations of the included trials, and had more favourable conclusions than the corresponding Cochrane (independent) reviews.
How profits, research mix at Stanford, Mercury News, July 9, 2006.
Can We Tame the Monster, British Medical Journal, July 8, 2006.
Commercial bias in medical journals: Commercial influence and the content of medical journals, by Joel Lexchin, Donald W Light, British Medical Journal, 2006; 332:1444-7.
Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry, by Lisa Cosgrove, Sheldon Krimsky, Manisha Vijayaraghavan, and Lisa Schneider, Psychotherapy and Psychosomatics, Psychother Psychosom 2006;75:154–160, DOI: 10.1159/000091772. This study found that 56% of the 170 DSM panel members had one or more financial associations with companies in the pharmaceutical industry and 100% of the members of the panels on "Mood Disorders" and "Schizophrenia and Other Psychotic Disorders" had financial ties to drug companies.
Drug trials: Stacking the deck: Studies of medical literature are confirming what many suspected — reporters of clinical trials do not always play straight. Jim Giles talks to those pushing for a fairer deal, Nature, 15 March 2006; | doi:10.1038/440270a.
The Effect of Conflict of Interest on Biomedical Research and Clinical Practice Guidelines: Can We Trust the Evidence in Evidence-Based Medicine?, by John Abramson, MD, MSFP, and Barbara Starfield, MD, MPH, Journal of the American Board of Family Practice, 2005, Vol. 18 No. 5: 414-18.
Ghost Authorship in Industry-Initiated Randomised Trials, by Peter C Gøtzsche, Asbjørn Hróbjartsson, Helle Johansen, Mette Haahr, Douglas G. Altman, An-Wen Chan, PLoS Medicine, 2005 January; 4(1): e19. Ghost authorship, found to be a very common practice in industry-sponsored trials, serves commercial interests and results in a lack of accountability.
Medical Students’ Exposure to and Attitudes About Drug Company Interactions: A National Survey, JAMA, September 7, 2005—Vol 294, No. 9, 1034-1042.
Psychiatry and the pharmaceutical industry: Who pays the piper?, by Moncrieff J, Hopker S, Thomas P., Psychiatric Bull. 2005;29:84-5.
As Universities Get Billions in Grants, Some See Abuses: Cornell Doctor Blows Whistle Over Use of Federal Funds, Alleging Phantom Studies, Wall Street Journal, August 16, 2005; Page A1
Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies, by Richard Smith, PLoS Med. 2005 May; 2(5): e138, Published online 2005 May 17. doi: 10.1371/journal.pmed.0020138.
Postmarketing Surveillance—Lack of Vigilance, Lack of Trust by Phil B. Fontanarosa, MD Drummond Rennie, MD Catherine D. DeAngelis, MD, MPH, Journal of the American Medical Association (JAMA), December 1, 2004—Vol 292, No. 21 2647.
Trial Registration: A Great Idea Switches From Ignored to Irresistible, by Drummond Rennie, MD, Journal of the American Medical Association (JAMA) September 15, 2004—Vol 292, No. 11 1359-1362.
How Tightly Do Ties Between Doctor and Drug Company Bind?, by By Abigail Zuger, M.D., New York Times, July 27,2004.
Clinical Trials Controversy Spotlights Flawed System, by Jim Rosack, Psychiatric News July 16, 2004, Volume 39 Number 14.
Medicine's Data Gap:Results of Drug Trials Can Mystify Doctors Through Omission, New York Times, July 21, 2004, By Barry Meier.
The Guardian, Foregone conclusions: The public is being regularly deceived by the drug trials funded by pharmaceutical companies, loaded to generate the results they need, Wednesday January 14, 2004.
Revealed: how drug firms 'hoodwink' medical journals. Pharmaceutical giants hire ghostwriters to produce articles - then put doctors' names on them. Antony Barnett, public affairs editor, Sunday December 7, 2003, The Observer
Stealth Merger: Drug Companies and Government Medical Research. Some of the National Institutes of Health's top scientists are also collecting paychecks and stock options from biomedical firms. Increasingly, such deals are kept secret. By David Willman. LA Times Staff Writer. December 7, 2003
Whistleblower's lawsuit could shake up the drug industry, by Theo Emery, Associated Press, August 9, 2003. An AP story about a lawsuit over Pfizer promoting fraudulent claims about neurontin's benefits.
Psychology in the Prescription Era: Building a Firewall Between Marketing and Science, by David O. Antonuccio, William G. Danton Terry Michael McClanahan, American Psychologist, Vol 48, No. 12, 1028-43 (2003).
Design and Reporting Modifications in Industry-Sponsored Comparative Psychopharmacology Trials, by Daniel Safer, Journal of Nervous and Mental Disorders, 2002, Vol. 190, No. 9, 583-592. Identifies and classifies specific techniques drug companies use to modify research design and reporting to serve marketing needs.
Transcript from Now with Bill Moyers, "Science for Sale?" (2002)
Debate Resumes on the Safety of Depression's Wonder Drugs," August 7, 2002 New York Times article describing the drug companies' hiding of data about the link between Selective Serotonin Reuptake Inhibitor (SSRI) anti-depression drugs and suicides, particularly in people 18 and under.
Scandal of scientists who take money for papers ghostwritten by drug companies: Doctors named as authors may not have seen raw data, Sarah Boseley, health editor, Thursday February 7, 2002, The Guardian
Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry, Niteesh K. Choudhry, M.D.; Henry Thomas Stelfox, M.D.: and Allan S. Detsky M.D., Journal of the American Medical Association, (February 6, 2002) V. 287, No.56, 102-617
Drug firms accused of distorting research, by Sarah Boseley, UK Guardian, September 10, 2001.
Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry, Thomas Bodenheimer, M.D., Health Policy Report (May 18, 2000, Vol. 342, No. 20, 1539-1544.
Is Academic Medicine For Sale, Marcia Angell, M.D., The New England Journal of Medicine, (May 18, 2000)
Accuracy of Data in Abstracts of Published Research Articles, by Roy M. Pitkin, MD, Mary Ann Branagan, Leon Fe. Burmeister, PhD, Journal of the American Medical Association, Vol 281, No. 12, 1110-1111 (1999).

FAIR USE NOTICE: These links may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available to advance understanding of ecological, political, human rights, economic, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, this material is used for non-profit educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. Any copyright owner who objects to the use of their copyrighted material should send an e-mail to webmaster@psychrights.org.